FDA grants orphan status to GW Pharmaceuticals' epilepsy candidate

11/18/2013 | Drug Store News

GW Pharmaceuticals' Epidiolex secured orphan-drug status from the FDA as a treatment for Dravet syndrome, a rare form of epilepsy that starts in infancy. The FDA allowed doctors to use the drug, which contains plant-derived cannabidiol, to treat 125 children with Dravet syndrome.

View Full Article in:

Drug Store News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
ABQ Health Partners
Albuquerque, NM
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Registered Dietitian I
University of Chicago Medicine
Chicago, IL
The Children's Aid Society
New York, NY